Involves Newly Diagnosed Malignant Glioma Patients
Note: This study is closed
The study evaluated the effects and determined the overall survival rates of newly diagnosed malignant glioma patients when administering a combination of bevacizumab (Avastin) and erlotinib (Tarceva) following the completion of radiation therapy with temozolomide (Temodar).
Other Avastin/Tarceva study objectives included:
- Determining the 12- and 18-month progression free survival
- Assess radiographic response rates
- Assess changes in tumor blood flow
- Collect safety data regarding the bevacizumab-erlotinib combination treatment following radiation and temozolomide
Participants remained in the study as long as they do not experience disease progression or incur unacceptable toxicity levels.
The study included 115 patients who participated up to one year. Results will be posted once the journal article is officially submitted.
For specific information on the Avastin/Terceva study, please click here.
Please contact us to obtain more information about the Avastin/Tarceva study.